Guardant Health secured FDA approval for its Guardant360 CDx blood test as a companion diagnostic for Pfizer’s Braftovi (encorafenib) plus cetuximab and chemotherapy in BRAF V600E‑mutant metastatic colorectal cancer, widening ctDNA testing’s companion diagnostic footprint. Separately, language in an appropriations spending package proposes a Medicare coverage pathway for multi‑cancer early detection (MCED) tests after FDA approval, setting a potential reimbursement route that could materially affect MCED business models and valuation. What happened: FDA granted a new CDx label to Guardant360, while Congress included a provision to streamline Medicare reimbursement for FDA‑cleared MCED tests under the appropriations bill. Sources: Guardant release, BioCentury item, and legislative summaries. Policy context: MCED reimbursement would lower a major commercial barrier; liquid biopsy CDx approvals continue to normalize ctDNA for treatment selection.